Amedeo Smart

Free Medical Literature Service


 

Amedeo

Autoimmune Disorders

  Free Subscription

04.07.2022

1 BMC Neurol
3 Diabetes
2 Intern Med
1 J Immunol
2 J Neurol
3 J Rheumatol
4 Mult Scler
2 Neurology
1 PLoS One
1 Thyroid



    BMC Neurol

  1. ZHANG Y, Chen HX, Shi ZY, Du Q, et al
    Brain structural and functional connectivity alterations are associated with fatigue in neuromyelitis optica spectrum disorder.
    BMC Neurol. 2022;22:235.
    >> Share


    Diabetes

  2. CARR ALJ, Inshaw JRJ, Flaxman CS, Leete P, et al
    Circulating C-Peptide Levels in Living Children and Young People and Pancreatic Beta Cell Loss in Pancreas Donors Across Type 1 Diabetes Disease Duration.
    Diabetes. 2022 May 2. pii: 146866. doi: 10.2337/db22-0097.
    >> Share

  3. YIP L, Alkhataybeh R, Taylor C, Fuhlbrigge R, et al
    Identification of Novel Disease-Relevant Genes and Pathways in the Pathogenesis of Type 1 Diabetes: A Potential Defect in Pancreatic Iron Homeostasis.
    Diabetes. 2022 May 2. pii: 146861. doi: 10.2337/db21-0948.
    >> Share

  4. CORVILLO F, Abel BS, Lopez-Lera A, Ceccarini G, et al
    Characterization and Clinical Association of Autoantibodies Against Perilipin 1 in Patients with Acquired Generalized Lipodystrophy.
    Diabetes. 2022 Jun 30. pii: 147153. doi: 10.2337/db21-1086.
    >> Share


    Intern Med

  5. NAGAYAMA Y, Edamoto M, Komine Y, Nakai H, et al
    Streptococcal Infection-related Glomerulonephritis in an Elderly Diabetic Patient Complicated by Hemophagocytic Syndrome and Cytomegalovirus Nephritis.
    Intern Med. 2022 Jun 28. doi: 10.2169/internalmedicine.9314.
    >> Share

  6. SHOBATAKE R, Kumazawa A, Koyama N, Takahashi N, et al
    Autoimmune Encephalitis Associated with Anti-N-methyl-D-aspartate Receptor and Anti-Hu Antibodies Successfully Treated with Carboplatin and Etoposide for Small-cell Lung Cancer.
    Intern Med. 2022 Jun 28. doi: 10.2169/internalmedicine.9707.
    >> Share


    J Immunol

  7. CHANG J, Bouchard A, Bouklouch Y, Panneton V, et al
    ICOS-Deficient Regulatory T Cells Can Prevent Spontaneous Autoimmunity but Are Impaired in Controlling Acute Inflammation.
    J Immunol. 2022 Jun 27. pii: jimmunol.2100897. doi: 10.4049/jimmunol.2100897.
    >> Share


    J Neurol

  8. CANNIZZARO M, Ferre L, Clarelli F, Giordano A, et al
    Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    J Neurol. 2022 Jun 27. pii: 10.1007/s00415-022-11227.
    >> Share

  9. SOROSINA M, Barizzone N, Clarelli F, Anand S, et al
    Correction to: A multi-step genomic approach prioritized TBKBP1 gene as relevant for multiple sclerosis susceptibility.
    J Neurol. 2022 Jun 25. pii: 10.1007/s00415-022-11216.
    >> Share


    J Rheumatol

  10. SUN K, Eudy AM, Criscione-Schreiber LG, Sadun RE, et al
    Racial Differences in Patient-provider Communication, Patient Self-efficacy, and Their Associations With Systemic Lupus Erythematosus-related Damage: A Cross-sectional Survey.
    J Rheumatol. 2021;48:1022-1028.
    >> Share

  11. CRAIG J, Feldman BM, Spiegel L, Dover S, et al
    Comparing the Measurement Properties and Preferability of Patient-reported Outcome Measures in Pediatric Rheumatology: PROMIS vs CHAQ.
    J Rheumatol. 2021;48:1065-1072.
    >> Share

  12. WALLACE ZS, Yun H, Curtis JR, Chen L, et al
    ANCA-associated Vasculitis Management in the United States: Data From the Rheumatology Informatics System for Effectiveness (RISE) Registry.
    J Rheumatol. 2021;48:1060-1064.
    >> Share


    Mult Scler

  13. PROUSKAS SE, Schoonheim MM, Huiskamp M, Steenwijk MD, et al
    A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?
    Mult Scler. 2022 Jun 28:13524585221103134. doi: 10.1177/13524585221103134.
    >> Share

  14. CREE BA, Selmaj KW, Steinman L, Comi G, et al
    Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
    Mult Scler. 2022 Jun 28:13524585221102584. doi: 10.1177/13524585221102584.
    >> Share

  15. MARASTONI D, Crescenzo F, Pisani AI, Zuco C, et al
    Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Mult Scler. 2022 Jun 28:13524585221104014. doi: 10.1177/13524585221104014.
    >> Share

  16. MAGNE F, Cellerino M, Balletto E, Aluan K, et al
    Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
    Mult Scler. 2022 Jun 28:13524585221103787. doi: 10.1177/13524585221103787.
    >> Share


    Neurology

  17. KENNEY RC, Liu M, Hasanaj L, Joseph B, et al
    The Role of OCT Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis.
    Neurology. 2022 Jun 28. pii: WNL.0000000000200883.
    >> Share

  18. TOOSY AT, Eshaghi A
    Machine Learning Utility for Optical Coherence Tomography in Multiple Sclerosis: Is the Future Now?
    Neurology. 2022 Jun 28. pii: WNL.0000000000200862.
    >> Share


    PLoS One

  19. PETRZALKA M, Meluzinova E, Libertinova J, Mojzisova H, et al
    IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
    PLoS One. 2022;17:e0270607.
    >> Share


    Thyroid

  20. MCLACHLAN SM, Rapoport B
    Discoveries in Thyroid Autoimmunity in the Past Century.
    Thyroid. 2022 Jun 29. doi: 10.1089/thy.2022.0275.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016